AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04794582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGrip™ Self-Gripping Polyester Mesh
Description: Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
Study NCT06214793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taletrectinib
Description: Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
Study NCT04816877 — intervention group
Intervention type: DRUG
Intervention: Opioid
Description: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
Study NCT06381375 — intervention group
Intervention type: OTHER
Intervention: Anti Tuberculosis Drug
Description: 1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events).
Study NCT04872465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS
Description: We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
Study NCT04872465 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham
Description: Participants will receive sham (placebo) TBS treatment the same as experimental group
Study NCT06050421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT)
Description: RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
Study NCT06050421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
Study NCT06050421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
Study NCT04787666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet
Description: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
Study NCT04754425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04754425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and bone marrow
Study NCT04754425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT06428747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).
Description: detection of micro-particles
Study NCT04800978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAVC-C+Durvalumab
Description: * Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion
Study NCT06155981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coke Zero
Description: Coca-Cola Zero Sugar drink will be given.
Study NCT06155981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coke
Description: Coca-Cola drink will be given.
Study NCT05449639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relief implantation
Description: The device will be implanted by endoscopic procedure by a standard resectoscope.
Study NCT05103761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study diet
Description: A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
Study NCT05103761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low glycemic index treatment diet
Description: A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
Study NCT06086912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
Study NCT06086912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
Study NCT06086912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
Study NCT05846581 — intervention group
Intervention type: DEVICE
Intervention: GORE® ACUSEAL Vascular Graft
Description: The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected.
Study NCT06636630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadruple scleral flap
Description: Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
Study NCT06636630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double scleral flap
Description: The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
Study NCT05578404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
Study NCT05578404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to Vit D
Study NCT04849234 — intervention group
Intervention type: BEHAVIORAL
Intervention: newborn cries
Description: Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne.
Study NCT06417281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Aminolevulinic Acid
Description: 3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
Study NCT06297538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gamma transcranial alternating current stimulation (tACS)
Description: Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
Study NCT06297538 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation (tACS)
Description: Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
Study NCT05801601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships
Description: The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
Study NCT05801601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A career readiness program
Description: Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
Study NCT05390697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
Study NCT04535037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Description: 3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
Study NCT04535037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP5-HBV-IPV-Hib
Description: 3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
Study NCT04535037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
Study NCT04535037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
Study NCT06096259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
Study NCT06096259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
Study NCT06030271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcatheter
Description: Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
Study NCT06320093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOUND Intervention
Description: The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
Study NCT04185701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SiVIEW software
Description: Eye examination by a technician with the SiVIEW software
Study NCT04185701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert
Description: Eye examination by an expert including optimal correction in distance and near vision
Study NCT05598645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: Participants will undergo treatment using the TFL
Study NCT05598645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOSES Holmium Laser
Description: Participants will undergo treatment using the MOSES Holmium laser.
Study NCT04696627 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants from all 3 groups will be interviewed
Study NCT05113862 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: LD Vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT05113862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LD PepGNP-Covid19
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT05113862 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: HD Vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT05113862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD PepGNP-Covid19
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT05540535 — intervention group
Intervention type: OTHER
Intervention: Gait assessment
Description: The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
Study NCT05540535 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
Study NCT04886869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: oral consumption
Study NCT04886869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: oral consumption
Study NCT06513988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI-BCI combined with tDCS treatment
Description: The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
Study NCT05527834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: Single oral dose
Study NCT05527834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: Single oral dose
Study NCT06298006 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
Study NCT04920760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplement
Description: The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children > 1 or for infants of \< 1 year of age, respectively).
Study NCT05205135 — intervention group
Intervention type: BEHAVIORAL
Intervention: SHARE Programme
Description: SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting.
Study NCT04823598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coached pushing and Finnish manual perineal protection
Description: Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin.